Skip to main content
SpringerLink
Log in

Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Seventeen patients were treated with echinomycin for metastatic renal cell carcinoma. Echinomycin is a bifunctional DNA intercalating agent with broad preclinical antitumor activity. It was given at 1200 mg/m2 by intravenous infusion over 30–60 min weekly for 4 weeks. The treatment was repeated every 6 weeks. There were no responses observed in the study. No life threatening or lethal toxicity was documented in 13 eligible patients. The median survival of these patients was 13.7 months. We conclude that echinomycin is not active against metastatic renal cell carcinoma at the dose and schedule tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris DT: Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 10:422–430, 1983

    Google Scholar 

  2. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310–7313, 1988

    Google Scholar 

  3. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180–199, 1992

    Google Scholar 

  4. Figlin RA, Abi-Aad AS, Belldegrun A, deKernion JB: The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma. Semin Oncol 18(Suppl 7): 102–107, 1991

    Google Scholar 

  5. Foster B, Clagett-Carr K, Shoemaker D, Suffness M, Plowman J, Trissel LA, Grieshaber CK, Leyland-Jones B: Echinomycin: the first bifunctional intercalating agent in clinical trials. Inves New Drugs 3:403–410, 1986

    Google Scholar 

  6. Lathan B, Von Hoff DD: Cytotoxic activity of echinomycin in a human tumor cloning system. Cancer Drug Deliv 1:191–198, 1984

    Google Scholar 

  7. Oken MM, Creech RM, Tormey DC, Morton J, Davis TE, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Rochester/Genesee Hospital, Rochester, NY

    Alex Y. Chang

  2. M.D. Anderson Cancer Center, Houston, TX

    Z. Nora Tu

  3. University of Wisconsin Cancer Center, Madison, WI

    George T. Bryan

  4. University of Pittsburgh, Pittsburgh, PA

    John M. Kirkwood & Martin M. Oken

  5. Virginia Piper Cancer Institute, Minneapolis, MN, USA

    Donald L. Trump

Authors
  1. Alex Y. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Nora Tu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George T. Bryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John M. Kirkwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin M. Oken
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Donald L. Trump
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, A.Y., Tu, Z.N., Bryan, G.T. et al. Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885. Invest New Drugs 12, 151–153 (1994). https://doi.org/10.1007/BF00874447

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874447

Key words

Search

Navigation